◈ Nootpedia

This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Compact view
Research pass: thorough Compound SKIP-FOR-NOW HIGH

Winstrol

Extended Research
High-risk compound

Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.

◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Editor's verdict SKIP-FOR-NOW HIGH

For a 20-year-old MMA athlete + business owner with peak endogenous testosterone, brain-priority + longevity orientation, and combat-sport training load, this is SKIP-AT-20 with HIGH confidence — and the tendon/ligament mechanism makes the verdict stronger than for most other AAS in this archetype. Stanozolol carries (1) the worst hepatotoxicity profile in the common 17α-aa class (multiple fatal cholestatic case reports — PMID 28856252, 37948000, 40040852, 40909442); (2) one of the worst lipid profiles of any AAS (HDL crash -33-53% per Thompson 1989 PMID 2915439; HTGL upregulation per Haffner 1983 PMID 6413814); (3) substantial SHBG suppression with downstream HPG suppression (Small 1984 PMID 6430603 — 55% testosterone reduction at 10mg/day x 14 days); (4) a coherent set of tendon/ligament/cartilage signals — reduced collagen synthesis enzymes in tendon (Karpakka 1992 PMID 1636855), stiffer + less-compliant tendons that fail at less elongation (Inhofe 1995 PMID 7778710), MMP downregulation impairing tendon remodeling (Marqueti 2006 PMID 16636352), 22% tendon rupture incidence in long-term AAS users vs 6% controls (Kanayama 2015 PMID 26362436); (5) "dry joints" community report consistently observed during cycles; (6) WADA S1.1 banned with detection windows up to 28 days oral / 2 months injectable. For an MMA athlete whose career rides on tendon, ligament, and joint integrity under high-velocity rotational and impact load, the tendon-rupture signal alone is verdict-determining — a torn pec, biceps, quadriceps, or Achilles ends a fight career. Verdict reverses ONLY for documented HAE prophylaxis (clinically vanishingly rare and would use newer C1-INH-targeted therapies instead) under specialist supervision.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • ★20yo MMA athlete + business owner, peak endogenous T, brain-priority, longevity orientation (the user)
    SKIP-AT-

    HIGH confidence. Tendon-rupture signal + hepatotoxicity + lipid profile combination makes Winstrol the worst-fit AAS for combat athletes specifically. Body composition + strength gains achievable through training + V4 stack (creatine, magnesium, DHA, etc.) + sleep optimization. The 20-year-old endogenous T peak (typically 600-900 ng/dL) means there is no anabolic deficit to correct.

  • ★20-30, brain-priority, no combat sport
    SKIP-AT-

    HIGH confidence. Same family logic. Tendon signal less acute but other risks (HPG, lipids, liver) unchanged.

  • 30-50, executive maintenance with documented hypogonadism
    SKIP

    TRT (testosterone replacement) is the appropriate intervention for documented hypogonadism, not an oral 17α-aa AAS.

  • 50+, mild cognitive decline
    SKIP

    no indication; cardiovascular + lipid + hepatic risk outweighs marginal body comp gains.

  • Anxiety-prone
    SKIP

    mood lability + post-cycle crash + libido changes amplify anxiety burden.

  • High athletic load, tested status (NCAA, USADA, WADA, professional combat sport)
    SKIP-PERMANENT

    during testing window — S1.1 banned with 28-day oral / 2-month injectable detection windows. No safe taper-to-test strategy exists.

  • High athletic load, untested status, non-combat sport
    SKIP

    as default. Risk profile (HPG suppression, atherogenic dyslipidemia, hepatotoxicity, tendon stiffness) independent of testing status.

  • Combat sport, untested or amateur
    SKIP-PERMANENT

    tendon-rupture risk is career-ending in combat sport. The Kanayama 22% vs 6% number is verdict-determining.

  • Sleep-disordered
    SKIP

    Winstrol can disturb sleep; no role in sleep optimization.

  • Recovery-focused (post-injury, post-illness, healthy young)
    SKIP

    for healthy young; tendon repair work better served by [bpc-157](bpc-157.md) + tb-500 + supportive nutrition/sleep — opposite mechanism (BPC-157 is collagen-supporting; Winstrol is collagen-impairing in tendon).

  • Strength/anabolic-focused, healthy young eugonadal
    SKIP

    for users in this archetype. The "track and field" reputation is real but the strength gains are achievable through other means without tendon liability.

  • Female athletes / fitness competitors
    W

    is one of the AAS sometimes used by women due to reasonable virilization risk profile at <10 mg/day; even so, virilization is irreversible at higher doses and the broader risk profile (HPG, lipids, liver, tendon) applies. Verdict for women's recreational use: SKIP unless competitive bodybuilding context with explicit informed consent.

▸ Subjective experience (deep)

At bodybuilder doses (30-50mg/day oral × 6-8 weeks, or 50mg EOD injectable)

  • Day 1-3: Subjective drive shift; libido often spikes early as free T rises (SHBG crash). Strength noticeable in gym within 3-5 sessions.
  • Week 1-2: Aesthetic shift begins — drier appearance, vascularity increasing, "harder" muscle quality. Strength climbing. Joint stiffness emerging in some users (especially shoulder + elbow + knee).
  • Week 2-4: Peak aesthetic phase — dry, hard, vascular look maximally expressed. Power output up. Lipid changes well-established on bloodwork; HDL crash measurable. Joint pain commonly reported in this window.
  • Week 4-6: Side-effect curve climbs. Libido may swing from initial spike to depression (HPG suppression catching up). ALT/AST starting to rise meaningfully on oral users; injectable slower.
  • Week 6-8: Cycle exit window. Hepatotoxicity risk rises with continued use; most users plan to stop here.
  • PCT (4-6 weeks post-cycle): HPG axis recovery; libido returns; lipids slowly normalize over 8-12 weeks; ALT/AST should normalize within 6-8 weeks. Mood crash possible in susceptible users.

Typical reported "characteristic effects"

  • Dry, hard, vascular aesthetic (the signature look — most pronounced of any AAS at modest doses)
  • Sharp strength + power gains, often disproportionate to mass gain
  • Joint stiffness and "dryness" (signature complaint)
  • Vivid pump that can be uncomfortable at high doses
  • Mood: typically neutral-to-positive early (free-T spike); mild irritability + anxiety in some users at higher doses
  • Sleep: variable; some users report stimulant-like insomnia
  • "Winstrol cough" — transient post-injection cough/chest tightness when injectable particles hit small venule (vasovagal-PE-mimicking phenomenon, frightening but typically resolves in seconds)
  • Lipid panel changes obvious on bloodwork
  • ALT/AST elevation universal at 4-6 weeks of oral use
  • Acne mild-to-moderate (DHT-derivative signaling)
▸ Tolerance + cycling deep dive
  • Tolerance buildup: AR receptor downregulation reported with chronic exposure; functional tolerance to anabolic effects develops over weeks-months. Standard convention 6-8 week cycles to limit hepatotoxicity + HPG burden.
  • Recommended cycle (bodybuilder convention): 6-8 weeks on, equal-or-longer off. Convention only — no clinical trial backing for healthy-adult body comp use.
  • Reset protocol: Off-cycle minimum 12 weeks; PCT (clomid + nolvadex, or enclomiphene) starts 1 week post-cycle and runs 4-6 weeks. HPG axis recovery generally 4-12 weeks; lipid recovery 8-16 weeks; LFT normalization 4-8 weeks. Tendon biomechanical changes may require longer (Damgaard 2025 patellar tendon data suggests incomplete reversibility in former users, though limited data).
▸ Stacking deep dive

Synergistic with (in bodybuilder protocols, NOT recommended for users in this archetype)

  • Testosterone esters (cypionate, enanthate): Standard "test base" — prevents total HPG crash, preserves libido during cycle. Common protocol: test enanthate 300-400 mg/week × 12 weeks + Winstrol 30-50 mg/day × last 6 weeks for cutting finisher.
  • anavar / oxandrolone: Both DHT-derivative orals, both 17α-alkylated — stacking compounds hepatotoxicity dramatically. Sometimes used in contest prep ("oral stacking") but widely cautioned against.
  • primobolan: DHT-derivative injectable (methenolone enanthate) often paired with Winstrol for cutting; primobolan adds anabolic without compounding hepatotoxicity (it's an injectable ester, not 17α-aa). The "milder cutting stack."
  • masteron-enanthate: Another DHT-derivative; similar hardening + anti-estrogen profile. Common contest-prep stack with Winstrol — compounds DHT-class side effects (joint dryness, hair loss in predisposed users).
  • Trenbolone: Synergistic for aggressive cutting; compounds cardiovascular + neurologic + lipid risks dramatically.
  • Clenbuterol / T3: Common cutting stack additions; compound cardiovascular load.
  • GH / IGF-1: Adds anabolic synergy + theoretical tendon support (collagen synthesis); compounds insulin resistance + cancer-pathway concerns.

Avoid stacking with

  • Other 17α-alkylated orals (methyltestosterone, fluoxymesterone, oxandrolone, dianabol, anadrol): Compounds hepatotoxicity dramatically; Winstrol is at the high end of C17-aa hepatotoxicity already.
  • anastrozole / aromatase inhibitors: Stanozolol is non-aromatizing — adding an AI on top crashes E2 below normal range, producing severe joint pain (already a Winstrol problem), low libido, lipid worsening. AIs are pharmacologically inappropriate during a Winstrol-only cycle.
  • Hepatotoxic medications (acetaminophen chronic, methotrexate, isoniazid, alcohol): Additive liver burden. Real-world collision for athletes using NSAIDs/acetaminophen for training pain.
  • Statins: Pharmacologically logical for crashing HDL/LDL but adds hepatic burden on top of an already-hepatotoxic 17α-aa drug. The appropriate move is to discontinue the AAS.
  • Warfarin / DOACs: Stanozolol potentiates warfarin significantly; per prescribing information, dose reduction with frequent INR monitoring required.

Compatible (mitigation, not justification)

  • tudca (tauroursodeoxycholic acid): Bile-acid liver-support supplement; mechanism-aligned for cholestatic protection. Reduces but does NOT eliminate Winstrol hepatotoxicity. Standard companion in bodybuilding harm-reduction protocols.
  • NAC (N-acetylcysteine): Glutathione precursor; antioxidant liver support. Reduces oxidative hepatic damage. Same caveat — does not make 17α-aa AAS safe.
  • Most non-hormonal nootropics (modafinil, citicoline, magnesium, fish oil — V4 stack): No direct interaction; the issue is the underlying inappropriateness of AAS at 20yo, not pharmacological collision.
▸ Drug interactions deep dive
  • Warfarin / anticoagulants: Stanozolol potentiates warfarin effect — dose reduction required, frequent INR monitoring (per Winstrol prescribing information).
  • Insulin and oral hypoglycemics: Modest insulin sensitivity changes possible; monitor glucose if applicable.
  • Hepatotoxic medications: Additive — avoid concurrent acetaminophen at chronic high doses, methotrexate, isoniazid.
  • CYP-mediated metabolism: Stanozolol is hepatically metabolized via CYP-mediated hydroxylation; specific CYP isoform involvement less characterized than for newer drugs. Expected interactions with strong CYP inhibitors are modest.
  • Detection (WADA): S1.1 Anabolic Androgenic Steroids, banned in- and out-of-competition. Detection via urine LC-MS/MS for parent + 3'-hydroxystanozolol + 17-epistanozolol-1'N-glucuronide metabolites — long detection window (oral ~28 days, injectable ~2 months) makes Winstrol particularly poor for tested athletes attempting to taper to clear before competition.
▸ Pharmacogenomics
  • AR (androgen receptor) CAG repeat length affects AR sensitivity per dose; not clinically actionable for AAS dosing decisions.
  • CYP polymorphisms affect stanozolol metabolism modestly; no validated pharmacogenomic dosing guidance.
  • SLCO1B1 / hepatic transporter variants may affect cholestasis risk (relevant across the C17-aa class).
  • Practical note: No pharmacogenomic test changes the SKIP-AT-20 verdict. Verdict is driven by indication / risk balance, not metabolic variability. The user's June 2026 23andMe results will not move this verdict.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Pharmaceutical-grade Rx (US) — Winstrol Effectively unavailable post-2010 N/A N/A Sanofi-Aventis withdrew the NDA in 2010. No FDA-approved stanozolol product currently in US market.
International pharmacy (Stromba, Stanazol, Stanabol, Strombafort, Menabol) Various $30-100/month Medium-High Available in Mexico, India, Eastern Europe; legitimate brands generally well-controlled; legal exposure for import varies.
Underground lab (UGL) tablets Common bodybuilding forum / telegram channels / dark markets $40-80/month at bodybuilder doses Low-Medium Frequently underdosed or counterfeit; common substitution with cheaper dianabol or methyltestosterone (multiple WADA failures attributed to "Winstrol I bought online"); third-party batch testing strongly recommended.
Underground lab (UGL) injectable Common offerings $50-100/month Low-Medium Counterfeit endemic; genuine product is white aqueous suspension — discolored, oil-based, or crystalline products are counterfeit. PIP + Winstrol cough are normal even with legitimate product.
Veterinary stanozolol Legitimately marketed for dogs/horses (Winstrol-V) Not relevant N/A Dosing entirely different from human; quality controlled to veterinary standards (lower than human pharmaceutical); not a recommended source.

For the user: Sourcing is solvable but counterfeit risk is high. Sourcing is not the gating question — appropriateness is. The tendon-rupture mechanism makes this SKIP-AT-20 at the user's profile regardless of sourcing path.

▸ Biomarkers to track (deep)

Baseline (before starting)

  • Liver: ALT, AST, GGT, alkaline phosphatase, total + direct bilirubin
  • Lipids: Full panel — LDL, HDL (with HDL2 subfraction if available), total cholesterol, triglycerides, ApoB, Lp(a)
  • HPG axis: Total + free testosterone, SHBG, LH, FSH, estradiol (sensitive assay), DHT, prolactin
  • Hematology: CBC (hematocrit baseline), ferritin
  • Cardiac: Blood pressure baseline, baseline echocardiogram if multi-cycle intent (Baggish protocol)
  • Metabolic: HbA1c, fasting glucose, eGFR
  • Combat-athlete-specific: Tendon palpation symmetry baseline (pec, biceps long head, biceps tendon at elbow, quadriceps tendon, patellar tendon, Achilles); document any tenderness or thickening
  • Joint comfort log: Baseline 0-10 ratings for shoulder, elbow, wrist, knee, ankle pain during specific movements (BJJ guard pull, kicking, striking transitions)

During use

  • Day 7: Lipid panel — early HDL crash detection (Haffner timeline: HDL drops 39% by day 7)
  • Week 4: ALT, AST, GGT, full lipid panel, blood pressure, hematocrit. Flag if ALT >3× ULN, HDL drops >50%, BP >140/90.
  • Week 4-6: Symptom check — any cholestatic symptom (jaundice, pruritus, dark urine, pale stools), any new tendon pain, any joint symptom escalation
  • Week 6-8: Repeat LFTs + lipids; cycle exit decision

End of cycle / post-cycle

  • Week 0 (cycle end): Full HPG panel (T, LH, FSH, E2, DHT) to quantify suppression; lipids; LFTs
  • Week 4 post-cycle: HPG recovery check; LFT normalization check
  • Week 8-12 post-cycle: Full lipid recovery check; HPG axis confirmation
  • Tendon symmetry recheck at week 4 + week 12 post-cycle; document any new tenderness or thickening

Long-term (multi-cycle users)

  • Annual lipid trend tracking
  • Periodic echocardiogram (Baggish protocol)
  • Liver imaging if any symptom or persistent transaminase elevation
  • Formal CVD risk recalculation with cumulative AAS exposure factored in
▸ Controversies / open debates Live debate

1. "Injectable Winstrol is safer for the liver than oral"

False. This is one of the most pernicious AAS-community myths. The active drug in injectable Winstrol Depot is the same 17α-methylated parent molecule as in oral tablets — it is hepatically metabolized regardless of route. The case reports of severe cholestatic hepatitis (PMID 28856252 — IM stanozolol; PMID 37948000 — oral stanozolol) include both routes. The molecular structure determines hepatotoxicity, not the delivery route. Injectable Winstrol is no safer for the liver than oral Winstrol. What the injectable does avoid is some of the gastric / first-pass kinetics of an oral dose, but the hepatic metabolism is unchanged.

2. Is the tendon signal really actionable for short cycles, or is the rat/rodent data overgeneralized?

The animal biomechanical data (Karpakka 1992, Inhofe 1995, Marqueti 2006) is robust and consistent across multiple labs. The Kanayama 2015 human cohort study (22% rupture rate vs 6%) is in long-term users (≥2 years cumulative AAS), not short-cycle users. The honest framing is: short cycles probably don't dramatically elevate tendon rupture risk in a single window, but the cumulative + multi-cycle risk is well-evidenced, and the mechanism (stiffer + less-compliant tendon, impaired remodeling) is operative even during a single cycle. For a combat athlete, the question is not "can I get away with one cycle without rupture" but "what is the expected value over a career with cumulative exposure?" Answer: tendon rupture probability rises meaningfully, and the cost of one rupture (career-ending pec / biceps / quadriceps / Achilles tear) is catastrophic. SKIP is the rational choice.

3. The Ben Johnson 1988 cultural moment

Stanozolol's cultural legacy is the September 24, 1988 Seoul Olympics 100m final, where Johnson ran 9.79s (then-world record) and beat Carl Lewis. Within 24 hours, Park Jong-sei at the Olympic Doping Control Center detected stanozolol metabolites in Johnson's urine. Disqualified within 72 hours; gold rescinded; the 1987 world record (9.83s) also rescinded after Johnson admitted to the Dubin Inquiry that he had been using AAS since 1981 under coach Charlie Francis. The cultural significance is that detection chemistry has improved enormously since 1988. Johnson's cycle was already detected in 1988; modern WADA labs detect 17-epistanozolol-1'N-glucuronide (Göschl 2021 — PMID 34089570) up to ~28 days post-oral-dose and 2 months post-injectable. Stanozolol is a particularly bad choice for tested athletes — it has the longest detection window of common cutting AAS, plus the most distinctive metabolic signature.

4. Stanozolol for HAE — historical importance vs modern relevance

Stanozolol's 1962 FDA approval was specifically for hereditary angioedema prophylaxis. The mechanism (increased hepatic C1-INH production via androgen-mediated transcription) is real and clinically useful. Multiple HAE specialist centers used stanozolol as a long-term prophylactic for decades. But: hepatotoxicity, lipid effects, and (in women) virilization made it poorly tolerated long-term. The development of targeted C1-INH replacement therapies (Cinryze, Berinert), bradykinin pathway antagonists (Takhzyro/lanadelumab — monoclonal antibody to plasma kallikrein, approved 2018), and oral kallikrein inhibitors (Orladeyo/berotralstat, approved 2020) made stanozolol obsolete for most HAE patients. Sanofi-Aventis withdrew the Winstrol NDA in 2010 — there is no FDA-approved stanozolol product currently marketed in the US. The "FDA-approved for HAE" is historical accuracy but not currently clinically relevant.

5. The "athletic strength without mass" reputation

Stanozolol has a reputation as the "track and field steroid" — favored by sprinters, throwers, and weight-class fighters specifically because it produces strength + power gains disproportionate to mass gain (compared to testosterone or trenbolone). This is real per user reports and the sprinter case-study evidence (Ben Johnson 9.79s). Mechanism may relate to (a) the SHBG crash producing rapid free-T spike → fast neuromuscular adaptation, (b) the non-aromatizable + low-water-retention profile producing "lean strength" without bloat, and (c) some evidence of Type II fiber preference. For weight-class combat athletes, this is the seductive feature — strength + power within a weight class without making weight cuts harder. And it is the reason combat athletes specifically should be most cautious — the same disproportionate strength outpaces tendon adaptation and elevates injury risk for the structures most loaded in combat.

6. Counterfeit endemic

Winstrol is one of the most counterfeited AAS due to its widespread sport use + relatively high price. Multiple WADA failures by athletes who claimed "I was on Winstrol" but tested for other AAS have been documented. UGL Winstrol tablets are commonly substituted with cheaper dianabol or methyltestosterone (which themselves are hepatotoxic and would still trigger lipid + LFT changes, contributing to the impression that "this is what Winstrol does"). UGL injectable Winstrol is sometimes oil-based knockoff (genuine product is white aqueous suspension). Sourcing reality contributes to risk profile beyond the molecule's intrinsic risks.

7. Long-term reversibility of tendon changes

Inhofe 1995 rat data showed partial recovery of tendon biomechanical changes by 12 weeks post-cessation. Damgaard 2025 patellar tendon study in former human AAS users showed some changes persisted. The honest framing is: short-term changes are largely reversible; cumulative multi-cycle changes may have persistent components. For a young athlete contemplating a "few cycles then stop," the framing should not be "I'll just stop and recover" — there is incomplete reversibility evidence in human cohorts.

▸ Verdict change log
  • 2026-05-10 (this file, thorough research) — SKIP-AT-20 HIGH confidence. Mechanism + evidence + side-effect profile + tendon-rupture cohort data + hepatotoxicity case reports + lipid mechanism + SHBG / HPG suppression + WADA detection profile all reviewed. The tendon-rupture mechanism is verdict-determining for the user as a 20yo MMA athlete — combat sport is full of high-velocity tendon and ligament loading, and the Kanayama 22% vs 6% cohort number plus the mechanism (stiffer + less-compliant tendon, impaired remodeling) plus the "dry joints" community report converge on a coherent career-risk story. Layered on hepatotoxicity (worst of common 17α-aa), worst lipid profile of common AAS, dramatic SHBG suppression, and WADA S1.1 with long detection window. Verdict reverses ONLY for documented HAE prophylaxis (clinically vanishingly rare and would use newer C1-INH-targeted therapies instead) under specialist supervision.
▸ Open questions / gaps Open
  • Short-cycle tendon risk in young athletes specifically: Most human evidence (Kanayama) is in long-term users; rat data (Inhofe, Marqueti) shows changes within weeks but the translation to acute-rupture risk in a single short cycle in a 20yo is extrapolation.
  • Reversibility of tendon biomechanical changes after short exposure: Limited human data; rat data suggests partial reversibility but Damgaard 2025 hints at incomplete reversibility in former users.
  • Specific tendon-targeting protocols (BPC-157, TB-500, IGF-1) co-administered with Winstrol — does the collagen-positive signal mitigate the Winstrol tendon-negative signal? Anecdotal community reports of "BPC-157 with cycle to protect tendons." No rigorous study; mechanism plausible (BPC-157 stimulates angiogenesis + Schwann cells + tendon fibroblast outgrowth — but does it specifically rescue stanozolol-impaired prolyl 4-hydroxylase + MMP function?). Speculative mitigation, not validated.
  • HDL recovery trajectory after short cycle: Limited prospective data. Case-series suggest 8-16 weeks for substantial recovery but incomplete in some users.
  • Long-term cardiac outcomes of 1-2 youth cycles: Largely unstudied. Baggish data is in long-term users with mixed AAS exposure.
  • Brain-development effects of supraphysiologic AR + SHBG-crashed environment in 20-25yo (prefrontal maturation window): Largely unstudied. Precautionary case favors skip.
  • Pharmacogenomic predictors of severe cholestatic response: Likely SLCO1B1 / ABCB11 / hepatic transporter variants matter; not validated for stanozolol specifically.
▸ Cross-references

Same-family AAS skip-at-20 cluster

  • oxandrolone — 17α-alkylated DHT-derivative oral; "milder" than stanozolol on hepatotoxicity + lipids + tendon signal but same family; SKIP-AT-20 same logic
  • primobolan (methenolone) — DHT-derivative; injectable methenolone enanthate is non-17α-aa (less hepatotoxic) but oral methenolone acetate is 17α-aa; SKIP-AT-20 same logic
  • masteron-enanthate — DHT-derivative injectable; non-17α-aa; less hepatotoxic but other AAS risks unchanged; SKIP-AT-20 same logic
  • testosterone-enanthate — base testosterone ester; aromatizable (E2-related risks added); SKIP-AT-20 unless documented hypogonadism

Counter-mechanism (collagen-supporting)

  • bpc-157 — pentadecapeptide that stimulates tendon healing, Schwann cell migration, VEGFR2-mediated angiogenesis; opposite mechanism to Winstrol's tendon impairment; STRONG-CANDIDATE for combat-athlete recovery work
  • TB-500 (Thymosin Beta-4 fragment) — actin regulator + connective tissue support; commonly stacked with BPC-157

Liver protection (mitigation only — does not justify the AAS)

  • tudca — bile acid; cholestatic protection
  • nac — glutathione precursor; antioxidant liver support

Estrogen management (not relevant for non-aromatizing Winstrol)

  • anastrozole — aromatase inhibitor; pharmacologically inappropriate during Winstrol-only cycle (already non-aromatizing); only relevant when stacking with aromatizable AAS

References

Small M et al. 1984 — Alteration of hormone levels in normal males given the anabolic steroid stanozolol (Clin Endocrinol)

pubmed.ncbi.nlm.nih.gov · 1984

PMID 6430603, 55% T reduction + SHBG crash

View Study

Sinnecker GH et al. 1989 — SHBG response to stanozolol (Acta Endocrinol)

pubmed.ncbi.nlm.nih.gov · 1989

PMID 2723028, basis of androgen-sensitivity test

View Study

Thompson PD et al. 1989 — Contrasting effects of testosterone and stanozolol on serum lipoprotein levels (JAMA)

pubmed.ncbi.nlm.nih.gov · 1989

PMID 2915439, head-to-head HDL crash comparison

View Study

Haffner SM et al. 1983 — Studies on metabolic mechanism of reduced HDL during anabolic steroid therapy (Metabolism)

pubmed.ncbi.nlm.nih.gov · 1983

PMID 6413814, HTGL upregulation mechanism

View Study

Applebaum-Bowden D et al. 1987 — Dyslipoproteinemia of anabolic steroid therapy (Metabolism)

pubmed.ncbi.nlm.nih.gov · 1987

PMID 3657514, HTGL precedes HDL drop

View Study

Stanozolol — Wikipedia

en.wikipedia.org

structural / pharmacokinetic / historical context

View Source

Baggish AL et al. 2017 — Cardiovascular toxicity of illicit AAS use (Circulation)

ahajournals.org · 2017

long-term cardiac MRI cohort

View Source

WADA Prohibited List 2025

wada-ama.org · 2025

S1.1 classification

View Source

FDA Winstrol Approval History (Discontinued)

accessdata.fda.gov · 1962

1962 approval, 2010 NDA withdrawal

View Source

Hero or villain? Ben Johnson and the dirtiest race in history (CNN)

edition.cnn.com · 1988

1988 Seoul Olympics scandal cultural reference

View Source

Latest research

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…
✎

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load ▸
Loading…